A Case-Control Study of TP53 R72P Polymorphism in the Breast Cancer Patients of Ethnic Kashmiri Population

Nidda Syeeda, A. Syed Sameerad, Safiya Abdullahad, Syed Akhtar Husainb, Mushtaq A Siddiqic

Abstract

Background: TP53 R72P polymorphism has been proposed as a risk factor for breast cancer and is more likely to differ among different ethnic populations. We carried out the study to determine the role of R72P polymorphism in breast cancer patients of Kashmir, an ethnic population by PCR-RFLP.

Methods: To evaluate the role of this polymorphism in our ethnic Kashmiri population, we devised our study to study its role in breast cancer patients and healthy controls. The contribution of TP53 R72P polymorphism in 130 breast cancer patients and 220 female healthy controls was assessed using a PCR-RFLP (polymerase chain reaction-restriction fragment length polymorphism).

Results: We observed that women with PP genotype have increased risk for developing breast cancer. We found Pro/Pro genotype statistically significantly associated with dwelling, lymph node metastases, histopathological grade, and menopausal status. Pro/Pro genotype in cases and controls was observed and it was found that it is significantly associated with the breast cancer.

Conclusions: Our findings suggest that TP53 R72P polymorphism is a risk factor in breast cancer. Furthermore, these results suggest Pro72 allele is associated with higher risk for breast cancer patients. Women with PP genotype have increased risk for developing breast cancer.

Keywords: Breast cancer; Tp53 polymorphism; Kashmir; R72P

Introduction

Breast cancer is one of the most common malignancies in women. It continues to be a major burden and cause of death among women worldwide. Worldwide, breast cancer is by far the most common cancer amongst women, with an incidence rate more than twice that of colorectal cancer and cervical cancer and about three times that of lung cancer. According to BIC database, majority of high risk families of different ethnicities, the germline mutations are scattered throughout both genes and are family specific.

Kashmir valley is located in the northernmost part of India. The Kashmir valley lies between Himalayas and the Pir Panjal Range, about 5000 ft from the sea level. The genetic makeup of the Kashmiri population is preserved due to consanguineous marriage that has lead to the preservation of the genetics of this population. The people of Kashmir constitutes a different set of dietary habits that have high percentage of nitroso compounds, amines and nitrates present in local food stuff [1-3] that consists of dried and smoked fish and meat, dried and pickled vegetables, red chilli, Hakh (a leafy vegetable of Brassica family), hot noon chai (salted tea) and Hukka (water pipe) smoke.

The TP53, a tumor suppressor gene plays a key role in preservation of genome integrity. The TP53 gene has been found mutated in various cancers including breast cancer [4], indicating its importance in cancer development, acting as a checkpoint control for recognizing damaged DNA and inducing repair or apoptosis [5]. Apart from the studies that have been carried out on the mutational status of TP53, there are many studies regarding the importance of the genetic polymorphisms of this gene. One of the important polymorphisms of TP53 gene occurs at codon 72 that encodes either proline or an arginine residue. TP53 protein with proline residue is structurally different from the one with arginine, and has functionally different role in inducing both apoptosis and cell cycle repair, in addition to affecting the function of somatic TP53 sequence variants [6, 7]. The arginine (arg) to proline change at codon 72 that is located in the proline-rich region of the protein and affects the structure of the putative SH3-binding domain. These two variant protein
forms behave differently: while the Arg/Arg genotype has been reported to induce apoptosis more effectively than the Pro/Pro genotype [7, 8], the Pro/Pro genotype appears to induce a higher level of G1 arrest than the Arg/Arg genotype [9, 10]. It has been seen that breast cancer patients with the Pro/Pro genotype of TP53 have poorer survival than those with other genotypes [11]. In addition, retention of the Arg allele of TP53 in tumor tissue samples of Arg/Pro heterozygous breast cancer patients has been associated with reduced disease-free and overall survival [12]. On the basis of this literature, we designed our study to determine the TP53 codon 72 genotype related to disease-free survival and overall survival of breast cancer affected patients.

Materials and Methods

Breast cancer patients

All breast cancer patients included in the study were both male and female, with the histopathological diagnosis of the breast cancer. The patient participation was obtained through informed consent and after approval from the Ethics Committee of Sher-I-Kashmir Institute of Medical Sciences.

A cohort of 130 breast cancer tissue samples were collected consisting of tumor tissues and adjacent normal tissue. Only the tissue samples confirmed by histopathological studies to be cancerous were included in the study.

Controls

Patients attending the Department of general medicine at Sher-I-Kashmir Institute of Medical Sciences (SKIMS) for general check up were screened. A total of 260 patients visited the SKIMS; out of 260 patients, only 220 agreed to take part in the present study, henceforth written informed consent was obtained from all patients for their participation.

R72P gene polymorphism

The exon 4 polymorphic site of TP53 codon 72 was detected by restriction fragment length polymorphism of PCR-amplified fragments. PCR reactions were carried out in a final volume of 25 μL containing 50 ng genomic DNA template,

| Table 1. Association Between TP53 Gene Codon 72 and Clinico-pathologic Characteristics |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|
| Variables                      | Cases (n = 130) | Total N = 130   | RR              | R/P             | PP              |
| Dwelling                       |                 |                 |                 |                 |                 |
| Rural:                         |                 |                 |                 |                 |                 |
| 45                             |                 | 29 (22.3%)      | 12              | 25 (55.55%)     | 0.52; 1.27     |
| Urban:                         |                 |                 |                 |                 |                 |
| 85                             |                 | 37 (28.4%)      | 27              | 48 (51.61%)     | 0.42; 1.69     |
| Smoking Status                 |                 |                 |                 |                 |                 |
| Never:                         |                 |                 |                 |                 |                 |
| 93                             |                 | 64 (49.2%)      | 12              | 25 (55.55%)     | 0.04; 6.16     |
| Ever:                          |                 |                 |                 |                 |                 |
| 37                             |                 | 29 (22.3%)      | 12              | 25 (55.55%)     | 0.04; 6.16     |
| Menopausal Status              |                 |                 |                 |                 |                 |
| Pre:                           |                 |                 |                 |                 |                 |
| 36                             |                 | 64 (49.2%)      | 12              | 25 (55.55%)     | 0.04; 6.16     |
| Post:                          |                 |                 |                 |                 |                 |
| 94                             |                 | 37 (28.4%)      | 12              | 25 (55.55%)     | 0.04; 6.16     |
| Nodal Status                   |                 |                 |                 |                 |                 |
| Involved                       |                 |                 |                 |                 |                 |
| 34                             |                 | 64 (49.2%)      | 12              | 25 (55.55%)     | 0.04; 6.16     |
| Not Involved                   |                 |                 |                 |                 |                 |
| 96                             |                 | 37 (28.4%)      | 12              | 25 (55.55%)     | 0.04; 6.16     |
| Tumor Stage                    |                 |                 |                 |                 |                 |
| II(a+b)                        |                 |                 |                 |                 |                 |
| 72                             |                 | 64 (49.2%)      | 12              | 25 (55.55%)     | 0.04; 6.16     |
| III(a+b)+ IV                   |                 |                 |                 |                 |                 |
| 58                             |                 | 29 (22.3%)      | 12              | 25 (55.55%)     | 0.04; 6.16     |
| Histopathological Tumor Grade  |                 |                 |                 |                 |                 |
| PD                             |                 | 25 (19.23%)     | 08              | 09 (36.0%)      | 0.04; 6.21     |
| MD + WD                        |                 | 58 + 47 (80.76%)| 21              | 55 (52.38%)     | 0.04; 6.21     |
1 x PCR buffer (Biotools) with 2 mM MgCl₂, 0.4 μM of each primer (Genescript), 50 μM dNTPs (Biotools), and 0.5 U DNA polymerase (Biotools). For PCR amplification, the standard program was used as follows: an initial denaturation step at 94°C for 7 min was followed by 35 denaturation cycles of 30 s at 94°C, 30 s of annealing at 54°C, and 30 s of extension at 72°C, and at last followed by a final elongation cycle at 72°C for 5 min. The amplified products (279bp) were detected on 2% agarose gel, along with a 100-bp DNA ladder. The 279-bp PCR products were digested for 16 h at 37°C with 1 unit of BstUI (Fermentas Inc, Vilnius, Lithuania); Arg/Arg wild produced two bands (160 and 119 bp); the Pro/Pro variant was identified by a single band (279 bp); and heterozygous Pro/Arg variant displayed three bands (279, 160, and 119 bp). The detection of the different alleles was carried out by horizontal ethidium bromide 4% agarose gel electrophoresis, along with a 100-bp DNA ladder.

Statistical analysis

Observed frequencies of genotypes in breast cancer patients were compared to controls using chi-square or Fisher exact tests when expected frequencies were small. The chi-square test was used to verify whether genotype distributions were in Hardy-Weinberg equilibrium. Statistical significance was set at P value less than 0.05. Statistical analyses were performed with PASW version 18 Software.

Results

We determined the TP53 codon 72 genotype in 130 breast cancer patients: 22.3% (29 of 130) of the patients were homozygous for R/R variant, 28.47% (37 of 130) were heterozygous for R/P and 49.2% (64 of 130) were homozygous for P/P variant. Our study consisted of 130 breast cancer patients, out of which 113 patients were below 50 years of age and 17 were of 50 years of age or more. Most of our patients (72) had grade I and II tumor, and 58 had grade III and IV tumor status. One hundred and five breast cancer patients had widely or moderately differentiated histopathological grade and 25 had poorly differentiated histopathological grade. Women aged 50 years or over formed the greater part of the breast cancer cases. Table 1 shows clinico-pathological characteristics related to the RR, RP and PP variants. A larger number of patients included in our study presented stages I and II than those who presented stages III and IV. Another clinical aspect investigated in this study was the relation between disease survival and Arg and Pro genotypes.

In this study we observed genotype frequencies in cases and controls were in Hardy-Weinberg equilibrium. The genotype frequencies of TP53 R72P in cases and controls were observed and it was found that PP genotype is significantly associated with the breast cancer cases (P value = 0.001) Table 2.

Discussion

Breast cancer is the most frequent neoplasm affecting women all over the world and is considered to be the third most common malignancy in the world [13] with more than 1 million women diagnosed with breast cancer each year [14]. Breast cancer has been associated with a variety of risk factors [15] of both genetic and epigenetic changes [16].

Kashmir is a small valley present at a high altitude, with mostly consanguineous marriages resulting in preservation
of the genetic pool. In addition, the unique dietary habit also results in predisposition to certain cancers including breast cancer. As has been reported earlier, breast cancer is a heterogeneous disease, and many risk factors are responsible in the development of breast cancer [17, 18]. It has been put forward that the frequency of TP53 codon-72 polymorphism varies according to ethnic group; hence we performed the study to analyze the role of TP53 R72P polymorphism in breast cancer patients in our ethnic population. The main aim of our study was to predict the predisposition towards the development of breast cancer due to single nucleotide polymorphism in TP53 codon 72.

TP53 is a classic tumor suppressor gene mutated in majority of human cancers including breast cancer. The main functions of TP53 are arresting cellular proliferation in response to various cellular stresses, including activated oncogenes, DNA damage, and hypoxia. As has been stated earlier [19], different ethnic populations express different TP53 polymorphisms and are selectively regulated; and it has also been observed that the R allele is activated during cancer development in Asians.

It has been shown by some studies [8] that TP53 Pro72 variant induces transcription activation more efficiently than TP53 Arg72 variant, and other studies have shown that TP53 Arg72 variant is more efficient in inducing apoptosis [7]. Few others showed TP53 Pro72 variant induces cell cycle arrest better than Arg72 [10]. In addition, to apoptosis and cell cycle control, p53 protein seems to be crucial in the regulation of the different DNA repair pathways [20]. A recent study revealed the ability of TP53 R72P in repairing the DNA damage, much more efficiently than the Arg72 variant expressing cells [21].

We included a total of 130 breast cancer patients; 22.3% (29 of 130) of the patients were homozygous for R/R variant, 28.47% (37 of 130) were heterozygous for R/P and 49.2% (64 of 130) were homozygous for P/P variant. Whereas the pattern of TP53 R72P polymorphism in 220 healthy controls, 16.3% (36 of 220) of the patients were homozygous for R/R variant, 48.6% (107 of 220) were heterozygous for R/P, and 30.4% (67 of 220) were homozygous for P/P variant. As has been stated earlier, [19] in Asians, R allele is more activated during cancer development, but in our study we found the P allele is much involved in the development and progression of breast cancer.

After the initial report of a statistically significantly increased risk of breast cancer in women who were homozygous for the proline allele [22], it has been found that PP variant leads to increased breast cancer risk [23], and it has also been found that R72 variant of wild-type p53 is almost five times more efficient in apoptosis induction than the P72 form, which is presumed to rely on the increased localization of the R72 form of TP53 in the mitochondria when compared with the P72 form [7].

We found a significant association of PP variant with certain clinico-epidemiological, as shown in Table 1. We found a significant association between PP variant and pre-menopausal status, suggesting that pre-menopausal breast cancer patients are more susceptible to breast cancer development and progression.

An increased association was found between the PP variant and involvement of lymph nodes, which might be due to the reason that PP variant might facilitate in stimulating axillary lymph node metastasis, which is in agreement with previously functional studies in the biological consequences of these variations in P53 protein functions [8]. To date axillary lymph node status is the best prognostic indicator in breast cancer [25, 26]. Therefore, present study might also act as a marker to indicate prognosis of breast cancer.

We also found a significant association between PP variant and tumor grade III and IV, which might suggest its role in harboring a higher malignant behavior.

A significant correlation was found between the PP variant and poorly differentiated histopathological grade as has been reported earlier [27], suggesting that TP53 germ-line and somatic mutations might be involved in different mechanisms and possibly also in different stages of tumor development.

We also found that the genotype frequencies of R72P in cases and controls, where PP genotype was significantly associated with the breast cancer cases (P value < 0.05), suggested that the breast cancer patients carrying a PP allele are at much higher risk for breast cancer.

**Conclusion**

We could conclude that in our population the PP variant might contribute to the development and progression of breast cancer. Two of the largest studies done of the polymorphism with breast cancer risk include more than 1000 subjects, however, no association of this polymorphism with breast cancer risk was reported [28, 29]. But in our population we suppose that it might be due to our environmental conditions and dietary habits that contribute for being at greater risk.

**Acknowledgements**

The present research was not funded by any funding agency. The collection of cancer samples used in this study was supported by the departments of immunology and molecular medicines and department of general surgery, Sher-i-kashmir institute of medical sciences.
The authors would like to thank all the breast cancer patients participated in the study who are responsible for the creation and maintenance of the entire group within which this study was conducted but were not involved in the current paper.

Authors’ Contributions

Nidda Syeed formulated, designed and performed the lab, work for the study; A. Syed Sameer and Safiya Abdullah helped in the lab work; and Syed Akhtar Husain and Mushtaq A. Siddiqi coordinated the study, revised the manuscript, and entire work was done under his supervision. All authors have read and approved the final manuscript.

Conflict of Interest

The contributing authors have no financial or any non-financial competing interests.

References

1. Cook-Mozaffari PJ, Azordegan F, Day NE, Ressicaud A, Sabai C, Aramesh B. Oesophageal cancer studies in the Caspian Littoral of Iran: results of a case-control study. Br J Cancer 1979;39(3):293-309.
2. Narang AP, Verma A, Kumar GR, Sanyal B. Serum copper levels in gastrointestinal tract (GIT) cancer. J Trace Elem Electrolytes Health Dis 1989;3(3):147-150.
3. Gibson RS. Content and bioavailability of trace elements in vegetarians diets. Am J Clin Nutr 1994;59(5 Suppl):1223S-1232S.
4. Feki A, Irminger-Finger I. Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit Rev Oncol Hematol 2004;52(2):103-116.
5. Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MM, Olivier M, Skomedal H, et al. Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma. Hum Mutat 2004;24(1):21-34.
6. Langerod A, Bukholm IR, Bregard A, Lonning PE, Andersen TI, Rognum TO, Meling GI, et al. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 2002;11(12):1684-1688.
7. Dumont P, Leu JI, Della Pietra AC, 3rd, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33(3):357-365.
8. Thomas M, Kalita A, Labrecque S, Pir D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999;19(2):1092-1100.
9. Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigante G, Attard M, Hiller L, et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004;23(19):3328-3337.
10. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004;108(2):196-199.
11. Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, Ristimaki A, et al. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 2005;11(14):5098-5103.
12. Bonafe M, Ceccarelli C, Farabegoli F, Santini D, Taffurelli M, Barbì C, Marzi E, et al. Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. Clin Cancer Res 2003;9(13):4860-4864.
13. Sipetic S, Petrovic V, Milic Z, Vlajmac H. [Breast cancer incidence among women of Braničevo region in the period 1991-2000]. Med Pregl 2004;57(9-10):467-472.
14. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-108.
15. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, Dossus L, et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 2005;12(4):1071-1082.
16. Xie GS, Hou AR, Li LY, Gao YN, Cheng SJ. Aberrant p16 promoter hypermethylation in bronchial mucosa as a biomarker for the early detection of lung cancer. Chin Med J (Engl) 2006;119(17):1469-1472.
17. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, et al. Molecular portraits of human breast tumours. Nature 2000;406(6797):747-752.
18. Dumitrescu RG, Cotarla I. Understanding breast cancer risk -- where do we stand in 2005? J Cell Mol Med 2005;9(1):208-221.
19. Siddique MM, Balram C, Fiszer-Maliszewska L, Aggarwal A, Tan A, Tan P, Soo KC, et al. Evidence for selective expression of the p53 codon 72 polymorphism: implications in cancer development. Cancer Epidemiol Biomarkers Prev 2005;14(9):2245-2252.
20. Osorio A, Martinez-Delgado B, Pollan M, Cuadros M, Urioste M, Torreteras C, Melchor L, et al. A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers. Hum Mutat 2006;27(3):242-248.
21. Sengupta S, Harris CC. p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell
22. Weston A, Pan CF, Ksieski HB, Wallenstein S, Berkowitz GS, Tartter PI, Bleiweiss IJ, et al. p53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev 1997;6(2):105-112.

23. Rajkumar T, Samson M, Rama R, Sridevi V, Mahji U, Swaminathan R, Nancy NK. TGFβ1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFβ1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemoradiotherapy. Breast Cancer Res Treat 2008;112(1):81-87.

24. Mir MM, Dar NA, Gochhait S, Zargar SA, Ahangar AG, Bamezai RN. p53 mutation profile of squamous cell carcinomas of the esophagus in Kashmir (India): a high-incidence area. Int J Cancer 2005;116(1):62-68.

25. Siddique M, Sabapathy K. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 2006;25(25):3489-3500.

26. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63(1):181-187.

27. Russo J, Frederick J, Ownby HE, Fine G, Hussain M, Krickstein HI, Robbins TO, et al. Predictors of recurrence and survival of patients with breast cancer. Am J Clin Pathol 1987;88(2):123-131.

28. Friedrichs K, Gluba S, Eidtmann H, Jonat W. Overexpression of p53 and prognosis in breast cancer. Cancer 1993;72(12):3641-3647.

29. Wang-Gohrke S, Becher H, Kreienberg R, Runnebaum IB, Chang-Claude J. Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics 2002;12(3):269-272.